Fed. Circ. Revives Axed Millennium Cancer Drug Patent
A Federal Circuit panel, in a precedential opinion on Monday, found that a Delaware federal court had wrongly ruled that a Millennium Pharmaceuticals Inc. cancer drug patent was invalid as obvious...To view the full article, register now.
Already a subscriber? Click here to view full article